Skip to main content
. 2016 Jun 21;66(650):e633–e639. doi: 10.3399/bjgp16X686533

Table 3.

Sensitivity analysis: cost effectiveness of amoxicillin in patients aged ≥60 years

Cost effectiveness excluding the cost of resistance
Difference in costs between amoxicillin and placebo groups, € (95% CI)a 0.34 (−6.55 to 7.23)
Difference in QALYs gained (95% CI) −0.0009 (−0.002 to 0.0002)
ICER Amoxicillin dominated
a

95% CIs.

ICER = incremental cost-effectiveness ratio. QALY = quality-adjusted life year.